GILDGilead SciencesNot started yet
Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy
Uterine Endometrial Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 100 (planned)
- Started
- Oct 2026
- Main results expected
- Sep 2029
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Measured over: Up to 3 years
Phase 1: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs)
Measured over: Up to 3 years
Phase 2: Overall Response Rate (ORR)
Measured over: Up to 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07743541 · record last updated 2026-08-05 · checked 2026-11-09 15:47 UTC